July 28th of each year is World Hepatitis Day. Chronic viral hepatitis causes 1.3 million deaths annually, most of which are due to liver cancer and liver cirrhosis—resulting in 3,500 deaths per day, equivalent in lethality to tuberculosis. Hepatitis B and C are spreading silently, with 6,000 new infections every day. Chronic hepatitis B and C can silently cause liver damage and cancer.
But we are not helpless: Hepatitis B can be prevented by vaccines, hepatitis C is completely curable, and hepatitis A, B, C, and E all have clear detection and treatment pathways. The World Health Organization (WHO) has long issued action guidelines: active testing, timely hepatitis B vaccination for newborns, learning about hepatitis, and eliminating disease stigma. [1]
As a company deeply engaged in the field of pathogen detection, iGeneTech has always taken technology as a shield to build a defense line for hepatitis prevention and control. Relying on the independently developed TargetSeq® liquid-phase probe hybridization capture technology with independent intellectual property rights, we have created whole genome sequencing solutions for hepatitis-related pathogens, covering core pathogenic viruses such as hepatitis B, C, A, and E, and provide early detection and early intervention through precise test.
01 Hepatitis B Virus (HBV) Panel
10,633 probes cover 8 subtypes (A-H) and the full length of 5,500 strain sequences. It accomplishes genotyping, detection of mutation sites, and analysis of integration sites between viral and host genomes in one test, providing a comprehensive basis for clinical diagnosis and treatment.
02 Hepacivirus Hominis (HCV) Panel
75,136 probes accurately capture viral information, facilitating precise diagnosis and treatment monitoring of hepatitis C.
03 Hepatitis A & E Virus (HAV & HEV) Panel
Designed with a total of 65,287 probes, it specifically covers the genomes of hepatitis A and E viruses, providing a reliable tool for the detection of gastrointestinal-transmitted hepatitis.
Order Information
CN
